Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001495734 | SCV001700423 | likely benign | not provided | 2025-01-20 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001495734 | SCV002000274 | uncertain significance | not provided | 2021-10-01 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV003298885 | SCV004004875 | uncertain significance | Inborn genetic diseases | 2023-03-20 | criteria provided, single submitter | clinical testing | The c.445A>G (p.N149D) alteration is located in exon 6 (coding exon 5) of the HPS4 gene. This alteration results from a A to G substitution at nucleotide position 445, causing the asparagine (N) at amino acid position 149 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV003948449 | SCV004759517 | likely benign | HPS4-related disorder | 2021-02-24 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |